<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03057691</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU1AF-CRF-2016-004</org_study_id>
    <nct_id>NCT03057691</nct_id>
  </id_info>
  <brief_title>The Impact of Depression and/or Anxiety on PCI Patients</brief_title>
  <official_title>The Impact of Major Depressive and/or Generalized Anxiety Disorder on Patients With Acute Coronary Syndrome After Percutaneous Coronary Interventions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shaanxi Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xi An No.1 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baoji Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The People's Hospital of Ningxia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuzhong People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the People's Hospital of Xinjiang Uygur Autonomous Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the First Division Hospital of Xinjiang Production and Construction Corps</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate how major depressive disorder or generalized anxiety
      disorder could effect the prognosis of the patients post-ACS after PCI and whether the
      treatment or improvement of depression and anxiety could improve their prognosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, multicentric, prospective real-world clinical study is going to assess if
      post-PCI major depressive disorder or generalized anxiety disorder could deteriorate major
      adverse cardiovascular events and all-cause mortality in patients suffered from acute
      coronary syndrome, also whether treatment of depression and anxiety or the improvement of
      their depression and anxiety could improve their major adverse cardiovascular events and
      all-cause mortality. Meanwhile, this study will also assess if post-PCI major depressive
      disorder or generalized anxiety disorder could impact the high sensitivity C-reaction
      protein, blood lipid, blood glucose, blood pressure and cardiac function to explore the
      potential mechanism.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiovascular Events</measure>
    <time_frame>From date of first visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>From date of first visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>all-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart failure</measure>
    <time_frame>From date of first visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>change from baseline at the 1st month, 3rd month, 6th month, 12th month, 18th month, 24month</time_frame>
    <description>blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting blood lipid</measure>
    <time_frame>change from baseline at the 1st month, 3rd month, 6th month, 12th month, 18th month, 24month</time_frame>
    <description>serum cholesterol, triglyceride, LDL, HDL, apoprotein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting blood glucose</measure>
    <time_frame>change from baseline at the 1st month, 3rd month, 6th month, 12th month, 18th month, 24month</time_frame>
    <description>fasting blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood routine examination</measure>
    <time_frame>change from baseline at the 1st month, 3rd month, 6th month, 12th month, 18th month, 24month</time_frame>
    <description>WBC, Hb, RBC, PLT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>routine urine test</measure>
    <time_frame>change from baseline at the 1st month, 3rd month, 6th month, 12th month, 18th month, 24month</time_frame>
    <description>the PH, protein, WBC, RBC of urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver and renal function</measure>
    <time_frame>change from baseline at the 1st month, 3rd month, 6th month, 12th month, 18th month, 24month</time_frame>
    <description>serum ALT, AST, TBIL, CR, BUN</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>MAjor Depressive Disorder</condition>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>patients suffered from ACS without major depressive disorder or generalized anxiety disorder after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDD impove</arm_group_label>
    <description>patients suffered from post-ACS major depressive disorder whose depression has been improved though antidepressive therapy or not after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDD not improve</arm_group_label>
    <description>patients suffered from post-ACS major depressive disorder whose depression hasn't been improved though antidepressive therapy or not after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GAD impove</arm_group_label>
    <description>patients suffered from post-ACS generalized anxiety disorder whose anxiety syndromes have been improved though anti-anxiety therapy or not after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GAD not improve</arm_group_label>
    <description>patients suffered from post-ACS generalized anxiety disorder whose anxiety syndromes havn't been improved though anti-anxiety therapy or not after PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>antidepressive and anti-anxiety therapy</intervention_name>
    <description>These therapies include antidepressants, antianxiety drugs and psychotherapy. Subjects choose the therapy follow their own will. All of the above-mentioned therapies are identified by experienced psychiatrists in the same center. The treatment information will be recorded in each visit. The study is considered non-interventional, and no antidepressive or anti-anxiety therapies are mandated.</description>
    <arm_group_label>MDD impove</arm_group_label>
    <arm_group_label>MDD not improve</arm_group_label>
    <arm_group_label>GAD impove</arm_group_label>
    <arm_group_label>GAD not improve</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients suffered from acute coronary syndrome after percutaneous coronary
        intervention
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. aged &gt; 24 years old

          2. patients with a diagnosis of ACS (ST-elevation MI, non-ST-elevation MI or unstable
             angina) and have undergone PCI with a good recovery

          3. within 12 months after PCI

          4. volunteer for the study and sign the informed consent

        Exclusion Criteria:

          1. Severe heart failure, defined as left ventricular ejection fraction (LVEF)≤30% or New
             York Heart Association (NYHA) class≥III

          2. Severe renal dysfunction, defined as serum creatinine≥451 umol/l

          3. Cancer

          4. Other severe mental illness including schizophrenia, severe dementia, substance abuse,
             etc

          5. Ongoing treated depression or anxiety during the onset of ACS

          6. Bipolar disorder

          7. Administration of antipsychotic, antidepressant, or antianxiety drugs during the onset
             of ACS

          8. Administration of monoamine oxidase inhibitors in 14 days before recruitment

          9. Serious risk of suicide

         10. Poor social support (predictable easy to be lost to follow-up)

         11. Allergic reaction to reasonable antidepressants or antianxiety drugs

         12. Severe medical condition (patients cannot finish the study course)

         13. pregnancy and lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zuyi Yuan, Professor</last_name>
    <role>Study Director</role>
    <affiliation>First Affiliated Hospital Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan Zhou, Professor</last_name>
    <phone>0086-18191037350</phone>
    <email>1306899042@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenyuan Li</last_name>
    <phone>0086-15191903966</phone>
    <email>lc3xlwy@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Zhou, Professor</last_name>
      <phone>0086-18191037350</phone>
      <email>1306899042@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Teply RM, Packard KA, White ND, Hilleman DE, DiNicolantonio JJ. Treatment of Depression in Patients with Concomitant Cardiac Disease. Prog Cardiovasc Dis. 2016 Mar-Apr;58(5):514-28. doi: 10.1016/j.pcad.2015.11.003. Epub 2015 Nov 10. Review.</citation>
    <PMID>26562328</PMID>
  </reference>
  <reference>
    <citation>Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, Freedland KE, Jaffe AS, Leifheit-Limson EC, Sheps DS, Vaccarino V, Wulsin L; American Heart Association Statistics Committee of the Council on Epidemiology and Prevention and the Council on Cardiovascular and Stroke Nursing. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation. 2014 Mar 25;129(12):1350-69. doi: 10.1161/CIR.0000000000000019. Epub 2014 Feb 24. Review.</citation>
    <PMID>24566200</PMID>
  </reference>
  <reference>
    <citation>Oldroyd JC, Cyril S, Wijayatilaka BS, O'Neil A, McKenzie DP, Zavarsek S, Sanderson K, Hare DL, Fisher AJ, Forbes AB, Barr Taylor C, Clarke DM, Meredith IT, Oldenburg B. Evaluating the impact of depression, anxiety &amp; autonomic function on health related quality of life, vocational functioning and health care utilisation in acute coronary syndrome patients: the ADVENT study protocol. BMC Cardiovasc Disord. 2013 Nov 17;13:103. doi: 10.1186/1471-2261-13-103.</citation>
    <PMID>24237848</PMID>
  </reference>
  <reference>
    <citation>Regan KL. Depression treatment with selective serotonin reuptake inhibitors for the postacute coronary syndrome population: a literature review. J Cardiovasc Nurs. 2008 Nov-Dec;23(6):489-96. doi: 10.1097/01.JCN.0000338929.89210.af. Review.</citation>
    <PMID>18953212</PMID>
  </reference>
  <reference>
    <citation>Ossola P, Paglia F, Pelosi A, De Panfilis C, Conte G, Tonna M, Ardissino D, Marchesi C. Risk factors for incident depression in patients at first acute coronary syndrome. Psychiatry Res. 2015 Aug 30;228(3):448-53. doi: 10.1016/j.psychres.2015.05.063. Epub 2015 Jun 27.</citation>
    <PMID>26144582</PMID>
  </reference>
  <reference>
    <citation>Huffman JC, Celano CM, Januzzi JL. The relationship between depression, anxiety, and cardiovascular outcomes in patients with acute coronary syndromes. Neuropsychiatr Dis Treat. 2010 May 6;6:123-36.</citation>
    <PMID>20505844</PMID>
  </reference>
  <reference>
    <citation>Celano CM, Millstein RA, Bedoya CA, Healy BC, Roest AM, Huffman JC. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. Am Heart J. 2015 Dec;170(6):1105-15. doi: 10.1016/j.ahj.2015.09.013. Epub 2015 Sep 21. Review.</citation>
    <PMID>26678632</PMID>
  </reference>
  <reference>
    <citation>Nezafati MH, Vojdanparast M, Nezafati P. Antidepressants and cardiovascular adverse events: A narrative review. ARYA Atheroscler. 2015 Sep;11(5):295-304. Review.</citation>
    <PMID>26715935</PMID>
  </reference>
  <reference>
    <citation>Marke V, Bennett P. Predicting negative emotional states following first onset acute coronary syndrome. J Health Psychol. 2017 May;22(6):765-775. doi: 10.1177/1359105315614996. Epub 2015 Nov 26.</citation>
    <PMID>26613707</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2017</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Generalized Anxiety Disorder</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Major Adverse Cardiovascular Events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

